Feeding Soy Protein Concentrates with Low and High Isoflavones Alters 9 and 18 Weeks Serum Isoflavones and Inflammatory Protein Levels in Lean and Obese Zucker Rats
Restricted accessResearch articleFirst published online February, 2023
Feeding Soy Protein Concentrates with Low and High Isoflavones Alters 9 and 18 Weeks Serum Isoflavones and Inflammatory Protein Levels in Lean and Obese Zucker Rats
Soy's anti-inflammatory properties contribute to the health benefits of soy foods. This study was designed to investigate the bioavailability of soy isoflavones and whether the isoflavone content of soy protein concentrate diet would affect serum inflammatory proteins in an obese (fa/fa) Zucker rat model. Six-week-old male lean (L) and obese (O) Zucker rats were fed a casein control diet (C), soy protein concentrate with low isoflavones (SPC-LIF), or soy protein concentrate with high isoflavones (SPC-HIF) (7 rats/dietary group) before being killed at 9 and 18 weeks. Serum samples were analyzed for isoflavones and inflammatory proteins. At both time points, serum total (aglycone + conjugates) genistein, daidzein, and equol concentrations were significantly higher in L-SPC-HIF and O-SPC-HIF groups compared with L-SPC-LIF and O-SPC-LIF groups, respectively, and were not detectable in either L-C or O-C groups. At week 9, serum C-reactive protein (CRP) concentration was significantly lower in O-SPC-HIF group compared with O-C and O-SPC-LIF group, whereas proteins tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) levels did not differ between any groups. At week 18, serum CRP levels in both O-SPC-HIF and O-SPC-LIF groups were significantly lower compared with the O-C group. TNF-α level was higher in the O-SPC-LIF group compared with both O-C and O-SPC-HIF groups, whereas IL-6 levels were not different between any groups. Taken together, feeding Zucker rats SPC-LIF and SPC-HIF diets led to different serum isoflavone concentrations in both L and O Zucker rats and altered CRP and TNF-α levels in obese Zucker rats compared with controls.
Get full access to this article
View all access options for this article.
References
1.
KawaiT, AutieriMV, ScaliaR. Adipose tissue inflammation and metabolic dysfunction in obesity. Am J Physiol Cell Physiol, 2021; 320(3):C375–c391; doi: 10.1152/ajpcell.00379.2020
2.
IyengarNM, GucalpA, DannenbergAJ, et al.Obesity and cancer mechanisms: Tumor microenvironment and inflammation. J Clin Oncol, 2016; 34(35):4270–4276; doi: 10.1200/jco.2016.67.4283
WuH, BallantyneCM. Metabolic inflammation and insulin resistance in obesity. Circ Res, 2020; 126(11):1549–1564: doi: 10.1161/CIRCRESAHA.119.315896
8.
McArdleM, FinucaneO, ConnaughtonR, et al.Mechanisms of obesity-induced inflammation and insulin resistance: Insights into the emerging role of nutritional strategies. Front Endocrinol, 2013; 4: doi:10.3389/fendo.2013.00052
9.
StahlEC, DelgadoER, AlencastroF, et al.Inflammation and ectopic fat deposition in the aging murine liver is influenced by CCR2. Am J Pathol, 2020; 190(2):372–387; doi: 10.1016/j.ajpath.2019.10.016
10.
TrouwborstI, BowserSM, GoossensGH, et al.Ectopic fat accumulation in distinct insulin resistant phenotypes; targets for personalized nutritional interventions. Front Nutr, 2018; 5:77; doi: 10.3389/fnut.2018.00077
11.
MitraS, DeA, ChowdhuryA. Epidemiology of non-alcoholic and alcoholic fatty liver diseases. Transl Gastroenterol Hepatol, 2019; 5:16.
12.
LazarusJV, MarkHE, AnsteeQM, et al.Advancing the global public health agenda for NAFLD: A consensus statement. Nat Rev Gastroenterol Hepatol, 2022; 19(1):60–78; doi: 10.1038/s41575-021-00523-4
13.
Al RifaiM, SilvermanMG, NasirK, et al.The association of nonalcoholic fatty liver disease, obesity, and metabolic syndrome, with systemic inflammation and subclinical atherosclerosis: The Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis, 2015; 239(2):629–633; doi: 10.1016/j.atherosclerosis.2015.02.011
14.
ForoughiM, MaghsoudiZ, KhayyatzadehS, et al.Relationship between non-alcoholic fatty liver disease and inflammation in patients with non-alcoholic fatty liver. Adv Biomed Res, 2016; 5:28; doi: 10.4103/2277-9175.176368
15.
TilgH, MoschenAR. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology, 2010; 52(5):1836–1846; doi: 10.1002/hep.24001
16.
KakinoS, OhkiT, NakayamaH, et al.Pivotal role of TNF-α in the development and progression of nonalcoholic fatty liver disease in a murine model. Horm Metab Res, 2018; 50(1):80–87; doi: 10.1055/s-0043-118666
17.
WandrerF, LiebigS, MarhenkeS, et al.TNF-Receptor-1 inhibition reduces liver steatosis, hepatocellular injury and fibrosis in NAFLD mice. Cell Death Dis, 2020; 11(3):212; doi: 10.1038/s41419-020-2411-6
18.
MessinaM.Soy and health update: Evaluation of the clinical and epidemiologic literature. Nutrients, 2016; 8(12):754; doi: 10.3390/nu8120754
19.
BadgerTM, RonisMJ, HakkakR, et al.The health consequences of early soy consumption. J Nutr, 2002; 132(3):559s–565s; doi: 10.1093/jn/132.3.559S
20.
HakkakR, KorourianS, ShelnuttSR, et al.Diets containing whey proteins or soy protein isolate protect against 7,12-dimethylbenz(a)anthracene-induced mammary tumors in female rats. Cancer Epidemiol Biomarkers Prev, 2000; 9(1):113–117.
ChatterjeeC, GleddieS, XiaoCW. Soybean bioactive peptides and their functional properties. Nutrients, 2018; 10(9):1211; doi: 10.3390/nu10091211
23.
KimI-S, YangW-S, KimC-H. Beneficial effects of soybean-derived bioactive peptides. Int J Mol Sci, 2021; 22(16):8570.
24.
KalaiselvanV, KalaivaniM, VijayakumarA, et al.Current knowledge and future direction of research on soy isoflavones as a therapeutic agents. Pharmacogn Rev, 2010; 4(8):111–117; doi: 10.4103/0973-7847.70900
25.
MiadokováE.Isoflavonoids—An overview of their biological activities and potential health benefits. Interdiscip Toxicol, 2009; 2(4):211–218; doi: 10.2478/v10102-009-0021-3
26.
MayoB, VázquezL, FlórezAB. Equol: A bacterial metabolite from the daidzein isoflavone and its presumed beneficial health effects. Nutrients, 2019; 11(9):2231; doi: 10.3390/nu11092231
27.
MaceTA, WareMB, KingSA, et al.Soy isoflavones and their metabolites modulate cytokine-induced natural killer cell function. Sci Rep, 2019; 9(1):5068; doi: 10.1038/s41598-019-41687-z
28.
BajerskaJ, ŁagowskaK, MoriM, et al.A meta-analysis of randomized controlled trials of the effects of soy intake on inflammatory markers in postmenopausal women. J Nutr, 2021; 152(1):5–15; doi: 10.1093/jn/nxab325
29.
SakaiT, KogisoM. Soy isoflavones and immunity. J Med Invest, 2008; 55(3–4):167–173; doi: 10.2152/jmi.55.167
30.
AsbaghiO, YaghubiE, NazarianB, et al.The effects of soy supplementation on inflammatory biomarkers: A systematic review and meta-analysis of randomized controlled trials. Cytokine, 2020; 136:155282.
31.
NagataC.Soy intake and chronic disease risk: Findings from prospective cohort studies in Japan. Eur J Clin Nutr, 2021; 75(6):890–901; doi: 10.1038/s41430-020-00744-x
32.
HakkakR, GaussCH, BellA, et al.Short-term soy protein isolate feeding prevents liver steatosis and reduces serum ALT and AST levels in obese female Zucker rats. Biomedicines, 2018; 6(2):55.
33.
HakkakR, ZengH, DhakalIB, et al.Short- and long-term soy diet versus casein protects liver steatosis independent of the arginine content. J Med Food, 2015; 18(11):1274–1280; doi: 10.1089/jmf.2015.0002
34.
HakkakR, Al-DwairiA, FuchsGJ, et al.Dietary soy protein induces hepatic lipogenic enzyme gene expression while suppressing hepatosteatosis in obese female Zucker rats bearing DMBA-initiated mammary tumors. Genes Nutr, 2012; 7(4):549–558; doi: 10.1007/s12263-012-0294-6
35.
KozaczekM, BottjeW, KongB, et al.Long-term soy protein isolate consumption reduces liver steatosis through changes in global transcriptomics in obese Zucker rats. Front Nutr, 2020; 7:607970; doi: 10.3389/fnut.2020.607970
36.
KozaczekM, KongB, BottjeW, et al.Hepatic proteomics analysis of nonalcoholic fatty liver disease obese rat model after short- and long-term soy protein isolate feeding. J Med Food, 2022; 25(3):293–302; doi: 10.1089/jmf.2021.0088
37.
HakkakR, SprayB, BørsheimE, et al.Diet containing soy protein concentrate with low and high isoflavones for 9 weeks protects against non-alcoholic fatty liver steatosis using obese Zucker rats. Front Nutr, 2022; 9:913571.
38.
DoergeDR, WoodlingKA, ChurchwellMI, et al.Pharmacokinetics of isoflavones from soy infant formula in neonatal and adult rhesus monkeys. Food Chem Toxicol, 2016; 92:165–176; doi: 10.1016/j.fct.2016.04.005
39.
ChuaSCJr., ChungWK, Wu-PengXS, et al.Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor. Science, 1996; 271(5251):994–996; doi: 10.1126/science.271.5251.994
40.
DurhamHA, TruettGE. Development of insulin resistance and hyperphagia in Zucker fatty rats. Am J Physiol Regul Integr Comp Physiol, 2006; 290(3):R652–R658; doi: 10.1152/ajpregu.00428.2004
41.
PhillipsMS, LiuQ, HammondHA, et al.Leptin receptor missense mutation in the fatty Zucker rat. Nat Genet, 1996; 13(1):18–19; doi: 10.1038/ng0596-18
42.
ZhengY, ZhangW, PendletonE, et al.Improved insulin sensitivity by calorie restriction is associated with reduction of ERK and p70S6K activities in the liver of obese Zucker rats. J Endocrinol, 2009; 203(3):337–347; doi: 10.1677/JOE-09-0181
43.
HsiaoY-H, HoC-T, PanM-H. Bioavailability and health benefits of major isoflavone aglycones and their metabolites. J Funct Foods, 2020; 74:104164; doi: 10.1016/j.jff.2020.104164
44.
de Almeida RoedigerM, de Fátima Nunes MarucciM, DuimEL, et al.Inflammation and quality of life in later life: Findings from the health, well-being and aging study (SABE). Health Qual Life Outcomes, 2019; 17(1):26; doi: 10.1186/s12955-019-1092-2
45.
FurmanD, CampisiJ, VerdinE, et al.Chronic inflammation in the etiology of disease across the life span. Nat Med, 2019; 25(12):1822–1832; doi: 10.1038/s41591-019-0675-0
46.
LuanY-Y, YaoY-M. The clinical significance and potential role of C-reactive protein in chronic inflammatory and neurodegenerative diseases. Front Immunol, 2018; 9:1302; doi: 10.3389/fimmu.2018.01302
47.
TracyRP, LemaitreRN, PsatyBM, et al.Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Arterioscler Thromb Vasc Biol, 1997; 17(6):1121–1127; doi: 10.1161/01.ATV.17.6.1121
48.
HallWL, VafeiadouK, HallundJ, et al.Soy-isoflavone-enriched foods and inflammatory biomarkers of cardiovascular disease risk in postmenopausal women: Interactions with genotype and equol production. Am J Clin Nutr, 2005; 82(6):1260–1268; doi: 10.1093/ajcn/82.6.1260
49.
AbdelrazekHMA, MahmoudMMA, TagHM, et al.Soy isoflavones ameliorate metabolic and immunological alterations of ovariectomy in female wistar rats: Antioxidant and estrogen sparing potential. Oxid Med Cell Longev, 2019; 2019:5713606; doi: 10.1155/2019/5713606
50.
GorissenSHM, CrombagJJR, SendenJMG, et al.Protein content and amino acid composition of commercially available plant-based protein isolates. Amino Acids, 2018; 50(12):1685–1695; doi: 10.1007/s00726-018-2640-5
51.
MurrayPJ.Macrophage polarization. Ann Rev Physiol, 2017; 79(1):541–566; doi: 10.1146/annurev-physiol-022516-034339
52.
AbronJD, SinghNP, PriceRL, et al.Genistein induces macrophage polarization and systemic cytokine to ameliorate experimental colitis. PLoS One, 2018; 13(7):e0199631; doi: 10.1371/journal.pone.0199631
53.
AbernathyLM, FountainMD, RothsteinSE, et al.Soy isoflavones promote radioprotection of normal lung tissue by inhibition of radiation-induced activation of macrophages and neutrophils. J Thorac Oncol, 2015; 10(12):1703–1712; doi: 10.1097/JTO.0000000000000677
54.
McNamaraDJ.Cholesterol homeostasis in lean and obese male Zucker rats. Metabolism, 1985; 34(2):130–135; doi: 10.1016/0026-0495(85)90121-0
55.
WangCS, FukudaN, OntkoJA. Studies on the mechanism of hypertriglyceridemia in the genetically obese Zucker rat. J Lipid Res, 1984; 25(6):571–579.
56.
BlayM, Peinado-OnsurbeJ, JulveJ, et al.Anomalous lipoproteins in obese Zucker rats. Diabetes Obes Metab, 2001; 3(4):259–270; doi: 10.1046/j.1463-1326.2001.00127.x
57.
AleixandreA, MiguelM. Zucker rats as an experimental model for the study of various diseases. Endocrinol Nutr, 2008; 55(5):217–222; doi: 10.1016/s1575-0922(08)70670-3
58.
BrayGA.The Zucker-fatty rat: A review. Fed Proc, 1977; 36(2):148–153.
PetersonRG, ShawWN, NeelM-A, et al.Zucker diabetic fatty rat as a model for non-insulin-dependent diabetes mellitus. ILAR J, 1990; 32(3):16–19; doi: 10.1093/ilar.32.3.16
61.
CapcarovaM, & KalafovaA.Zucker diabetic fatty rats for research in diabetes. In: Animal Models in Medicine and Biology. (Tvrdá E, Yenisetti SC. ed.) IntechOpen: London, UK; 2019.
62.
BaiW, WangC, RenC. Intakes of total and individual flavonoids by US adults. Int J Food Sci Nutr, 2014; 65(1):9–20; doi: 10.3109/09637486.2013.832170
63.
ChunOK, ChungSJ, SongWO. Estimated dietary flavonoid intake and major food sources of U.S. adults. J Nutr, 2007; 137(5):1244–1252; doi: 10.1093/jn/137.5.1244
64.
MulliganAA, KuhnleGG, LentjesMA, et al.Intakes and sources of isoflavones, lignans, enterolignans, coumestrol and soya-containing foods in the Norfolk arm of the European Prospective Investigation into Cancer and Nutrition (EPIC-Norfolk), from 7d food diaries, using a newly updated database. Public Health Nutr, 2013; 16(8):1454–1462; doi: 10.1017/s1368980012003904
